tradingkey.logo

Drugmaker Merus drops on $300 mln stock offering

ReutersJun 4, 2025 10:27 AM

U.S.-listed shares of Merus NV MRUS.O down 6.5% to $58.34 before the bell after follow-on priced

Dutch biotech firm early Weds announced ~5.3 mln shares at $57 for $300 mln gross proceeds

Offering priced at 8.7% discount to stock's last sale

Co plans to use net offering proceeds to advance clinical development of its product candidates, for preclinical research and technology development, and for working capital among other purposes

Through Tues close, MRUS shares surged 50% since May 22, when co said its lead candidate petosemtamab in combination with Merck's MRK.N Keytruda delayed progression of a type of head and neck cancer in a mid-stage trial

Co has ~69.2 mln shares outstanding for $4.3 bln market cap

Jefferies, BofA, Leerink, Guggenheim, Truist and LifeSci Capital are jt bookrunners for the offering

All 17 analysts covering MRUS are bullish, including 7 "strong buy" ratings, with $88.50 median PT, latest LSEG data reflects

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI